HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis.

AbstractOBJECTIVE:
Antileukoproteinase (ALP) is a physiologic inhibitor of granulocytic serine proteases. The present study was undertaken to investigate its therapeutic benefit in an antibody-transfer model of erosive polyarthritis and to elucidate its potential to interfere with immune complex-dependent inflammatory pathways.
METHODS:
Arthritis development was induced in male (BALB/c x B10.Q)F(1) mice by intravenous injection of two monoclonal antibodies specific for type II collagen and was quantified by clinical scoring and histopathology. Arthritis severity was assessed in a cohort of mice under systemic treatment with recombinant human ALP (daily doses of 0.1 mg for 5 days starting immediately after disease induction) in comparison with untreated controls. Concomitantly, functional assays (phagocytosis, oxidative burst, fluorescence-activated cell sorting analysis of integrin expression) were performed on neutrophils upon in vitro stimulation by IgG-coated latex beads.
RESULTS:
ALP treatment reduced arthritis incidence and severity and had a protective effect against cartilage and bone erosion. ALP inhibited the conversion of the leukocyte beta2 integrins into an active conformation upon Fc receptor stimulation of granulocytes. ALP bound to the actin-bundling protein L-plastin and down-modulated filamentous actin assembly in response to stimulation with IgG-coated latex beads in granulocytes. ALP exerted additional inhibitory effects on neutrophil functions associated with cytoskeletal reorganization, such as phagocytosis and oxidative burst.
CONCLUSION:
In addition to its antiprotease activity, ALP exerts a variety of blocking effects on neutrophil functions, probably due to modulation of cytoskeletal changes, that may contribute to this inhibitor's antiarthritis potential and qualify it as a multifunctional regulator of inflammatory responses.
AuthorsBettina Sehnert, Andrea Cavcic, Beate Böhm, Joachim R Kalden, Kutty Selva Nandakumar, Rikard Holmdahl, Harald Burkhardt
JournalArthritis and rheumatism (Arthritis Rheum) Vol. 50 Issue 7 Pg. 2347-59 (Jul 2004) ISSN: 0004-3591 [Print] United States
PMID15248236 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Actins
  • Antibodies, Monoclonal
  • Collagen Type II
  • Integrins
  • Membrane Glycoproteins
  • Microfilament Proteins
  • Phosphoproteins
  • Proteinase Inhibitory Proteins, Secretory
  • Proteins
  • Recombinant Proteins
  • plastin
Topics
  • Actins (chemistry, metabolism)
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Arthritis, Experimental (immunology, metabolism, pathology, physiopathology)
  • Cell Membrane Permeability
  • Collagen Type II (immunology)
  • Cytosol (metabolism)
  • Humans
  • Integrins (metabolism)
  • Joints (drug effects, pathology)
  • Leukocytes (metabolism)
  • Male
  • Membrane Glycoproteins
  • Mice
  • Mice, Inbred Strains
  • Microfilament Proteins (metabolism)
  • Neutrophils (drug effects)
  • Phagocytosis (drug effects)
  • Phosphoproteins (metabolism)
  • Proteinase Inhibitory Proteins, Secretory
  • Proteins (pharmacology)
  • Recombinant Proteins (pharmacology)
  • Respiratory Burst (drug effects)
  • Severity of Illness Index
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: